Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMF5XQH)

• Drug Name: Methoxamine Drug Info
• Synonyms: Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol
• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 6082
  ChEBI ID: CHEMBL524
  CAS Number: CAS 390-28-3
  TTD Drug ID: D09GYT
  VARIDT Drug ID: DR01182

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Proteasome	2.25	0.00e+0	44/46 (95.65%)	PSMD11;PSMB8;PSMC1;...
Graft-versus-host disease	2.24	0.00e+0	32/42 (76.19%)	HLA-DQA1;HLA-DRA;GZMB;...
Autoimmune thyroid disease	2.16	0.00e+0	46/53 (86.79%)	HLA-DQA1;HLA-DRA;GZMB;...
Antigen processing and presentation	2.15	0.00e+0	60/78 (76.92%)	HSPA4;HSPA2;HSPA8;...
Allograft rejection	2.09	1.64e-3	32/38 (84.21%)	HLA-DQA1;HLA-DRA;GZMB;...
Type I diabetes mellitus	2.06	1.37e-3	38/43 (88.37%)	HLA-DQA1;HLA-DRA;GZMB;...
Spliceosome	1.99	1.17e-3	101/150 (67.33%)	HSPA2;HSPA8;HNRNPA1;...
Ribosome biogenesis in eukaryotes	1.94	1.03e-3	52/108 (48.15%)	REXO5;GNL3L;GNL3;...
Cysteine and methionine metabolism	1.92	1.82e-3	43/50 (86%)	ENOPH1;ADI1;BCAT1;...
RNA polymerase	1.81	7.39e-3	23/31 (74.19%)	POLR2K;POLR3C;POLR2B;...
DNA replication	1.72	2.39e-2	34/36 (94.44%)	PRIM2;POLE2;RPA2;...
RNA transport	1.71	2.67e-2	128/186 (68.82%)	SUMO3;PRMT5;THOC6;...
Inflammatory bowel disease	1.70	2.46e-2	58/65 (89.23%)	HLA-DQA1;HLA-DRA;TGFB2;...
Intestinal immune network for IgA production	1.69	2.46e-2	38/48 (79.17%)	HLA-DQA1;HLA-DRA;HLA-DRB1;...
Fanconi anemia pathway	1.67	3.01e-2	36/54 (66.67%)	REV3L;RPA2;BLM;...
Base excision repair	1.66	3.44e-2	29/33 (87.88%)	PARP2;POLE2;APEX1;...
ECM-receptor interaction	-1.76	2.68e-2	80/88 (90.91%)	LAMC2;ITGA7;VWF;...
Focal adhesion	-1.78	2.90e-2	180/201 (89.55%)	LAMC2;ITGA7;VWF;...
Arrhythmogenic right ventricular cardiomyopathy	-1.79	3.20e-2	70/77 (90.91%)	PKP2;CACNB3;ITGA1;...
Steroid biosynthesis	-1.84	1.81e-2	19/20 (95%)	LBR;CYP24A1;DHCR24;...
Dilated cardiomyopathy	-1.93	1.13e-2	86/96 (89.58%)	CACNB3;ITGA1;EMD;...
Hypertrophic cardiomyopathy	-2.08	0.00e+0	81/90 (90%)	CACNB3;ITGA1;EMD;...
Cardiac muscle contraction	-2.16	0.00e+0	64/87 (73.56%)	TPM1;SLC9A1;ATP1A3;...
Mineral absorption	-2.23	0.00e+0	48/60 (80%)	FXYD2;ATP1B3;CYBRD1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼